

Amendments to the Claims

Please amend Claims 1, 5 and 9. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (currently amended) A method of treating asthma in a human in need thereof ~~an individual~~ comprising administering to the human ~~individual~~ a therapeutically effective amount of an anti-TNF α antibody or an antigen binding fragment thereof.
2. (original) The method of Claim 1 wherein the antibody is a chimeric antibody.
3. (previously presented) The method of Claim 2 wherein the chimeric antibody competitively inhibits binding of TNF α to the cA2 monoclonal antibody.
4. (original) The method of Claim 2 wherein the chimeric antibody is the cA2 monoclonal antibody.
5. (currently amended) A method of treating airway inflammation associated with asthma in a human in need thereof ~~an individual~~ comprising administering to the human ~~individual~~ a therapeutically effective amount of an anti-TNF α antibody or an antigen-binding fragment thereof.
6. (original) The method of Claim 5 wherein the antibody is a chimeric antibody.
7. (original) The method of Claim 6 wherein the chimeric antibody competitively inhibits binding of TNF α to the cA2 monoclonal antibody.
8. (original) The method of Claim 6 wherein the chimeric antibody is the cA2 monoclonal antibody.
9. (currently amended) A method of reducing accumulation in lungs of inflammatory cells associated with asthma in a human ~~an individual~~ in need thereof comprising

administering to the human individual a therapeutically effective amount of an anti-TNF α antibody or an antigen-binding fragment thereof.

10. (original) The method of Claim 9 wherein the antibody is a chimeric antibody.
11. (original) The method of Claim 10 wherein the chimeric antibody competitively inhibits binding of TNF α to the cA2 monoclonal antibody.
12. (original) The method of Claim 10 wherein the chimeric antibody is the cA2 monoclonal antibody.